# A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

> **NCT07106671** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- CRS - Cytokine Release Syndrome
- Myeloma

## Interventions

- **DRUG:** Siltuximab

## Key facts

- **NCT ID:** NCT07106671
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-10
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07106671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07106671, "A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07106671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*